sorrento therapeutics, inc....sorrento therapeutics, inc. (the “company”) intends to conduct...
TRANSCRIPT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 4, 2013
SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
6042 Cornerstone Ct. West, Suite B San Diego, CA 92121
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 210-3700
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Delaware 000-52228 33-0344842(State or other jurisdiction
of incorporation or organization) (Commission File Number)
IRS Employer Identification No.)
� Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
� Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
� Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
� Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Sorrento Therapeutics, Inc. (the “Company”) intends to conduct meetings with third parties in which its corporate slide presentation will be presented. The Company’s presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 4, 2013
Item 7.01 Regulation FD Disclosure
Item 9.01. Financial Statements and Exhibits
99.1 Sorrento Therapeutics, Inc. Company Presentation
SORRENTO THERAPEUTICS, INC.
By: /s/ Richard Vincent Name: Richard VincentTitle: Chief Financial Officer and Secretary
Exhibit 99.1
E
xhibit991
SorrentoT
herapeuticsN
extG
enerationC
ancerT
herapeuticsO
ctober2013
Safe
Harbor
StatementO
TC
QB
:SRN
ET
hispresentation
contains“forw
ard-lookingstatem
ents”as
thattermis
definedunder
theP
rivateS
ecuritiesL
itigationR
eformA
ctof1995
(PSL
RA
)including
statements
regardingexpectations
beliefsor
intentionsregarding
ourbusiness
technologiesand
productsstrategies
orprospects
Actualresults
may
differfrom
thoseprojected
dueto
anum
berof
risksand
uncertaintiesincluding
butnotlimited
tothe
possibilitythatsom
eor
allof
thepending
matters
andtransactions
beingconsidered
bythe
Com
panym
aynotproceed
ascontem
platedand
byallother
matters
specifiedin
Com
pany’sfilings
with
theS
ecuritiesand
Exchange
Com
mission
asw
ellasrisks
inherentinfunding
developingand
obtainingregulatory
approvalsof
newcom
mercially-viable
andcom
petitiveproducts
andproductcandidates
Sufficiency
ofthe
datafor
approvalwith
respecttoC
ynviloq™w
illbea
reviewissue
afterN
DA
filingT
hesestatem
entsare
made
basedupon
currentexpectationsthatare
subjecttorisk
anduncertainty
andinform
ationavailable
tothe
Com
panyas
ofthe
dateof
thispresentation
The
Com
panydoes
notundertaketo
updateforw
ard-lookingstatem
entsin
thispresentation
toreflectactualresults
changesin
assumptions
orchanges
inother
factorsaffecting
suchforw
ard-lookinginform
ationA
ssumptions
andother
information
thatcouldcause
resultsto
differfrom
thosesetforth
inthe
forward-looking
information
canbe
foundin
theC
ompany’s
filingsw
iththe
Securitiesand
Exchange
Com
mission
includingits
mostrecentperiodic
reportW
eintend
thatallforward-looking
statements
besubjectto
thesafe-harbor
provisionsof
theP
SLR
A2
M
anagementT
eamand
Board
ofD
irectorsH
enryJi
Ph
DPresident
CE
O&
Director
Inventorof
G-M
AB
®T
echnologyP
resident&C
EO
ofS
tratageneG
enomics
VP
ofC
ombiM
atrixand
Stratagene
Vuong
Trieu
Ph
DC
hiefScientific
Officer
Founderand
CE
Oof
IgDraS
olCo-inventor
ofIP
coveringA
braxane®Instrum
entalinthe
approvalofA
braxane®C
elgeneacquired
Abraxis
Biosciences
for>
$3billion
George
Uy
Chief
Com
mercialO
fficerC
CO
ofIgD
raSolDirected
thelaunches
ofA
braxane®X
eloda®&
Fusilev®
Builtcom
mercialinfrastructures
andorganizations
instartup
companies
Richard
VincentC
FOand
Director
$430Msale
ofE
levationto
Sunovion-D
ainipponM
eritagePharm
aoption
agreementw
ithV
iroPharm
a($90M
upfront+m
ilestones)$310M
saleof
Verus
asthma
programto
AstraZ
enecaE
lan:variousacquisitions
anddivestitures
with
aggregatevalues
inexcess
of$300M
Board
ofD
irectorsD
avidW
ebbPh
D—
Chairm
anC
elgene(form
erSan
Diego
sitehead)
Ernst-G
üntherA
ftingM
DP
hD
Hoechst(form
erPresident)
Cam
Gallagher
Nerveda
LL
C(M
anagingD
irector)K
imD
JandaPh
DT
heScripps
Research
Institute(Prof
)H
enryJi
Ph
DSorrento
(CE
O)
MScottS
alkaA
mbitB
iosciences(form
erC
EO
)Jaisim
Shah
PDL
(former
CB
O)
Vuong
Trieu
Ph
DSorrento
(CSO
)R
ichardV
incentSorrento
(CFO
)3
Investm
entHighlights
Late
StageO
ncologyD
rugw
ithE
xclusiveU
Sand
EU
Rights
Addresses
multi-billion
dollarpaclitaxelm
arketA
bbreviatedregulatory
pathway
(“bioequivalence”)for
approvalB
ioequivalenceregistration
trialin2014
(studydirectcosts
~$5M
)Productlaunch
in1H
2016T
herapeuticantibody
engineA
ntibodym
arket>$50B
in2012
Firstantibodydrug
candidatein
clinic1H
2015T
argetedD
rugD
eliveryC
ombining
Antibody
asspecific
targetingw
arheadSm
allMolecule
Drug
aspotenttum
orkilling
payloadT
oxinfor
Antibody
Drug
Conjugates
(AD
C)
PaclitaxelforA
ntibodyform
ulatedD
rugC
onjugates(A
fDC
)C
ynviloq™G
-MA
B®
AD
C/A
fDC
4
Sorrento’s
Next-G
enerationC
ancerT
herapeuticsC
ynviloq™N
ext-generationA
braxane®B
ioequivalence(B
E)
pathway
forapproval
Efficacy
demonstrated
US
andE
Urights
G-M
AB
®H
igh-diversityhum
anA
blibrary
Lead
mA
bprogram
sinclude
PD-L
1P
D-1
andC
CR
2FT
Oand
nostacking
royaltiesA
fDC
:Antibody
formulated
Drug
Conjugate
G-M
AB
targetsapproved
chemotherapeutics
tothe
tumor
Effective
againstheterogeneoustum
orsA
DC
:Antibody
Drug
Conjugate
G-M
AB
targetstoxin
tocancer
cellProgram
sinclude
VE
GFR
2c-M
et5
PipelineIN
DIC
AT
ION
PHA
SE2
PH
AS
E3
ND
AF
ILIN
GM
etastaticB
reastCancer
}505(b)(2)B
ioequivalenceN
on-SmallC
ellLung
Cancer
PancreaticC
ancer(B
E*
orsN
DA
)B
ladderC
ancer(sN
DA
)O
varianC
ancer(sN
DA
)C
ynviloq™G
-MA
B®
AD
CA
fDC
IND
ICA
TIO
N>
TA
RG
ET
PRE
CL
INIC
AL
PHA
SE1
Oncology
>PD
-L1
PD-1
CX
CR
51H
2015Inflam
mation
>C
CR
2C
XC
R3
2H2015
InfectiousD
isease>
MR
SAC
diffO
ncology>
VE
GF
R2
c-Met
CX
CR
5E
GF
R2H
2015O
ncology>
PD-L
1V
EG
FR2
c-Met
1H2014
1H2015
Multiple
Strategic
PartnershipO
pportunities*
Abraxane®
orphandrug
status(FD
Aapproval
Septem
ber2013)
6
O
ncologyFranchise
Cynviloq™
Phase3
7
C
ynviloqis
the3rd
Generation
PaclitaxelTherapy
Generation
Formulation
Maxim
umT
oleratedD
osePeak
ProductSales
1stT
axol®paclitaxel
Crem
ophorE
Lexcipient:P
olyoxyethylatedcastor
oil175
mg/m
2~
$16B
(WW
in2000)
2ndA
braxane®nab-paclitaxelM
ean130
sizenm
Donor-derived
Biologicalpolym
er:human
serumalbum
in(H
SA
)260
mg/m
2E
st>
$17B
*(U
S)($430M
in2012)
3rdC
ynviloq™paclitaxelpolym
ericm
icelleM
eansize
~25nm
Chem
icalpolymer:P
oly-lactideand
polyethyleneglycoldiblock
copolymer
>300
mg/m
2(up
to435
mg/m
2)C
onversionof
Abraxane®
sales+
newindications*A
nalystprojection;in
Metastatic
BreastC
ancer+
Non-S
mallC
ellLung
Cancer
+Pancreatic
Cancer
8
C
ynviloqis
aH
ighV
alueP
roposition1
Exclusive
US
andE
UR
ights2
Cynviloq
efficacydem
onstratedin
Phase
2and
Phase
3studies
3F
DA
concurreda
Available
datasupportpursuing
505(b)(2)regulatory
pathway
bB
ioequivalence(B
E)
studysufficientfor
approvalofindications
inA
braxane®label(M
etastaticB
reastCancer
andN
onSm
allCell
Lung
Cancer)
4L
argem
arketopportunitya
Abraxis
(Abraxane®
)sold
toC
elgenefor
>$3B
b$1
7Bin
projectedU
Speak
revenuesfor
Abraxane®
9
B
ioequivalence=
EfficientP
athway
toM
arketB
ioequivalenceregistration
studyin
breastcancerpatients
(2014)12
months
ofduration
(includingpatientrecruitm
ent)D
irecttrialcost~$5MC
ycle1
Cycle
2A
braxane®(50
patients)A
braxane®C
ynviloq™(50
patients)C
ynviloq™D
ose:260m
g/m2
Infusiontim
e:30m
inD
uration:3w
eeks+
crossoverfor
3w
eeksE
ndpoints:AU
Cand
Cm
ax(90%
CI)
10
C
ynviloqM
arketOpportunity
~70000
patientstreated
with
paclitaxelbased
regimen
in1stline
#of
PatientsT
reatedin
1stline(U
SO
nly;2012)100
00090
00080
00070
00060
00050
00040
00030
00020
00010
00030
76615
90314
4799
880N
SCL
CM
BC
Pancreatic
Cancer
Ovarian
Cancer
n=
93800
n=
38000
n=
27000
n=
17700
Other
regimens
PAC
+treated
~55000
patientsw
ithpaclitaxelas
1stlinetherapy
inM
BC
NSC
LC
&O
C15
903P
Cpatients
eligiblefor
treatmentw
ithA
braxane®+
Gem
citabinecom
binationN
ote:InPancreatic
Cancer
theblue
portionrepresents
#patients
treatedw
ithgem
basedR
xin
2012Sources:U
Sinform
ationSE
ER
AnnualC
ancerR
eview1975
2006;US
Census;M
attsonJack;U
HC
andM
edicareC
laims;IntrinsiQ
;SynovateT
andemW
HO
mortality
database2008
http://ww
ww
hoint/w
hosis/whosis/
World
Population
Prospects
The
2008R
evisionU
NP
opulationD
ivision2009
http://esaun
org/unpp/R
ocheG
enentechC
linicalPatientC
hartAudits
Totalpatientnum
bersrepresenttreatable
population1stL
inepatient
estimates
fromIntrinsiQ
2012M
onthlyL
OT
Diag
Com
bo11
C
ynviloqA
dvantagesC
ynviloq™A
braxane®T
axol®C
ynviloqA
dvantageM
aximum
Tolerated
Dose
(mg/m
2)>
300260175Potentialfor
higherefficacy
Rapid
reconstitution:nofoam
ingconcerns
Convenience
forbusy
practicesand
pharmacies
No
donor-derivedhum
anserum
albumin
(HSA
)N
oviral/prion
concernsC
onvenientstorageconditions
No
requirementfor
controlledtem
pstorage
No
microbialgrow
thC
hemicalpolym
erC
remophor-free
Reduced
sideeffects
Dosing
q3wq3w
*&
weekly**
q3w&
weekly
Exploits
PKadvantage
@higher
dose*
=M
BC
;**=
NSC
LC
&PC
12
Potentialto
Expand
LabelIndications
–For
Exam
ple:2ndL
ineB
ladderC
ancerC
ynviloqPhase
2(K
orea)*260-300
mg/m
2q3w
n=34#
BestSupportive
Care
Phase2
(Japan)**/P
hase3
(EU
)***n=
23**/n=
108***O
verallResponse
Rate
(OR
R)
21%-
/0%***
ProgressionF
reeS
urvival2
7M
-/1
5M
***O
verallSurvival
65
M2
3M
**/4
3M
***Sum
mary:
High
unmetneed—
noF
DA
-approved2nd
linedrug
Dem
onstratedclinicalO
verallResponse
Rate
(OR
R)
Phase3-ready
fordevelopm
entas2nd
linechem
otherapyin
patientsrefractory
toplatinum
-basedtherapy
#advanced
urothelialcarcinoma
patientsrefractory
togem
citabineand
cisplatin**
AU
ASan
Diego
May
4th8th;***
JCO
(2009):445461
13 *InvestN
ewD
rugs(2012)
30:1984–1990
N
extSteps
forC
ynviloq1
Bioequivalence
(BE
)trial:2014
2N
DA
filing:2014/2015
3A
pproval:2015/2016
aM
etastaticB
reastCancer
(MB
C)
andN
onSm
allCellL
ungC
ancer(N
SCL
C)
bF
utureA
braxane®indications
(Pancreaticcancer
andM
elanoma)
4P
roductlaunchfor
MB
Cand
NS
CL
C:2016
5sN
DA
planningfor
labelexpansioninto
Bladder
andO
variancancers
Bioequivalence
Trial
ND
AF
ilingFD
AA
pprovalL
AU
NC
H2014
2014/20152016
201614
T
herapeuticA
ntibodyE
ngineG
MA
B®
Extensive
Pipeline15
G
-MA
B®
:Library
ofT
herapeuticA
ntibodies-
RN
Aam
plificationused
for2
1x
1016distinctantibodies
librarygeneration
-F
reedom-T
o-Operate
•F
ullyhum
anantibodies
DifficultT
argets:Sm
allPeptides
MostD
ifficultTargets:
High
Value
Oncology
Targets:G
Protein
Coupled
Receptors
Imm
unomodulation:P
D1
andP
DL
1(G
PC
Rs)
Antibody
Drug
Conjugates:c
Met;V
EG
FR2
Sizeof
TargetA
ntigenA
IP1
AIP
2A
IP3
AIP
416 •
Proprietarytechnology
Very
highlibrary
diversity:•
No
stackingroyalties
High
successfulscreeninghitrate
A
nti-PD
-L1
mA
bsE
xhibitPotentA
ctivityIm
mune
Modulation*
Tum
orM
ouseM
odel**T
CellA
ctivation(%
)403020100IFN
-?(pg/m
L)
15000120009000600030000IL
-2(pg/m
L)
8006004002000T
umor
Grow
thInhibition
(%)
504030201001525DayC
ompetitor
mA
bSorrento
mA
b**
xenograftmodelusing
H1975
human
NS
CL
Ccells;%
inhibitionrelative
tocontrolm
Ab
treatment
***p<
005
mean
tumor
volumes
aresignificantly
reducedin
ST
IA
1010group
versuscontrolgroups
asdeterm
inedby
Mann
Whitney
utest
17 *m
Abs
@0
05m
g/mL
A
nti-PD
-1m
Abs
ExhibitP
otentImm
uneM
odulationIL
-2C
oncentration(pg/m
L)
10008006004002000IN
F-?
Concentration
(pg/mL
)150001000050000T
cellActivation
(%C
D25+
)norm
alizedto
untreatedcontrol
252015100Competitor
mA
bsSorrento
mA
b18 5
Potent A
ntibody against Difficult G
PCR
Target*
Disease Score**
mA
b Cell B
inding (E
C50 –nM
) Sorrento 0.17 C
ompetitor 21
Untreated Sorrento m
Ab
3.5 2.5 1.50
5013
1415
1617
1819
2021
2223
2425
2627
2829
3031
3233
3435
3637
38D
aysA
fterD
iseaseInduction
**E
xperimentalA
utoim
mune
Encephalom
yelitis(E
AE
)=
murine
modelof
Multiple
Sclerosis
19 321*Sorrento
mA
bagainstC
-CC
hemokine
Receptor
2(C
CR
2)
T
argetedD
rugF
ormulation
PlatformA
DC
/AfD
CG
MA
B®
+Payload
20
A
ntibody Drug C
onjugates (AD
C)
Key C
omponents: 1 A
DC
in plasma
1T
argetspecific
internalizingantibody
2P
otentcytotoxicprodrugs
3L
inkerand
conjugationchem
istriesD
rugreleased
inC
AN
CE
RC
EL
L21 2
AD
Cbinds
toreceptor
3A
DC
isinternalized
4C
ytotoxicagentis
released5
Apoptosis
(celldeath)
Sorrento
AD
Cs
Dem
onstrateE
nhancedA
ctivityA
nti-VE
GF
R2
AD
C*
Anti-c-M
etAD
C**
Relative
CellV
iability(%
ofnon
treatedcells)
100500000010
0010
010
1p
value<0
0001100
8060
4020
00
00010
0010
010
11
pvalue<0
0001IgG
Concentration
(nM)
Viability
Relative
IgGC
oncentration(nM
)L
eadingC
ompetitor
mA
bT
oxinC
ontrolSorrento
AD
C(m
Ab
+T
oxin)**
Hum
anA
549N
SC
LC
Cells
22 1*H
uman
Vascular
EndothelialC
ells(H
UV
EC
s)
Sorrento
anti-GPC
RA
DC
sD
emonstrate
Enhanced
Activity
Anti-C
XC
R3
AD
C*
Anti-C
XC
R5
AD
C**
Relative
CellV
iability(%
ofnon
treatedcells)
150100
500
-500
0010
010
11
10100
500
0001
001
01
10IgG
Concentration
(nM)
(%of
nontreated
cells)of
nontreated
cells)IgG
Concentration
=p
00035**value
=p
00015**value
Sorrentonaked
mA
bT
oxinC
ontrolSorrento
AD
C(m
Ab
+T
oxin)IgG
Concentration
(nM)
**C
ellsexpressing
human
CX
Cchem
okinereceptor
5(C
XC
R5)
23 *C
ellsexpressing
human
CX
Cchem
okinereceptor
3(C
XC
R3)
A
ntibody formulated D
rug Conjugates (A
fDC
) K
ey Features:
1. Approved chem
otherapeutics with know
n safety profile 2. N
o internalization required 3. M
ultiple mA
bs / drug combinations
4. Effective against heterogeneous tum
ors T
UM
OR
Drug
releasedin
TU
MO
R24 1
AfD
Cin
plasma
2A
fDC
bindsto
cancerantigens
andenriches
intum
or3
Cytotoxic
agentisreleased
andenters
tumor
cells
G
MA
B®
AD
Cand
AfD
CPipeline
GM
AB
®A
ntibodyPD
L1
(STI
A100X
)1H
2015PD
L1
(STI
A100X
)A
fDC
PD1
(STI
A110X
)1H
2015O
NC
OL
OG
YV
EG
FR2
AD
C(S
TI
A0168)
2H2015
EG
FR(ST
IA
020X)
AD
C/A
fDC
cM
et(ST
IA
150X)
AD
C/A
fDC
PDL
1(ST
IB
010X)
INF
LA
MM
AT
ION
RA
GE
(ST
IB
120X)
CG
RP
(STI
B150X
)C
CR
2(S
TI
B020X
)2H
2015O
NC
OL
OG
Y/C
CR
2(S
TI
B020X
)A
DC
INF
LA
MM
AT
ION
(GP
CR
)C
XC
R3
(STI
A120X
)A
DC
CX
CR
5(ST
IB
030X)
AD
CIN
FE
CT
IOU
SM
RSA
(STI
C020X
)D
ISE
ASE
Multiple
Strategic
PartnershipO
pportunities25
Positioned
toB
ecome
Oncology
Leader
Cynviloq™
GM
AB
®A
DC
/AfD
CPhase
3E
xtensivePipeline
GM
AB
+P
ayload26
Sm
allMolecule
Oncology
Drug
Antibody
Library
andA
DC
Com
panyV
aluationsC
ompany
Sm
allMolecule
Antibody
Targeted
MktC
ap*O
ncologyD
rugPlatform
Drug
Delivery
NSC
LC
MB
CA
ntibodySorrento:SR
NE
AD
C&
AfD
C$130M
(Ph3/R
egistrationT
rial)L
ibraryPum
a:PB
YI
MB
C(P
hase3)
~$16B
Pre-revenueC
lovis:CL
VS
NSC
LC
MB
C(P
hase1)
~$19B
Pre-revenueM
orphoSys:M
OR
DE
Antibody
~$20B
Pre-revenueL
ibraryC
AT
:Acquired
(2006)A
ntibody~$1
4BPre-revenue
Library
Dom
antis:Acquired
(2007)A
ntibody~$450MPre-revenue
Library
SeattleG
enetics:SG
EN
AD
C~$5
4BP
roductsales+
royaltyIm
munoG
en:IMG
NA
DC
~$15B
Royalty
only27 *
basedon
publicly-availableinform
ation(09/26/13)
Investm
ent Highlights
Cynviloq™
G
-MA
B®
A
DC
/AfD
C
Late Stage O
ncology Drug w
ith Exclusive U
S and E
U R
ights T
herapeutic antibody engine T
argeted Drug D
elivery Com
bining 28 •
Addresses
multi-billion
dollarpaclitaxelm
arket•
Abbreviated
regulatorypathw
ay(
bioequivalence)
forapproval
•B
ioequivalenceregistration
trialin2014
(studydirectcosts
~$5M
)•
Productlaunchin
1H2016
•A
ntibodym
arket>$50B
in2012
•Firstantibody
drugcandidate
inclinic
1H2015
•A
ntibodyas
specifictargeting
warhead
•Sm
allMolecule
Drug
aspotenttum
orkilling
payload•
Toxin
forA
ntibodyD
rugC
onjugates(A
DC
)•
PaclitaxelforA
ntibodyform
ulatedD
rugC
onjugates(A
fDC
)
Financials
&C
apitalizationC
ashand
Cash
Equivalents
$5
7MT
otalDebt$
50M
Com
mon
StockO
utstanding16
479734
Options
Granted
&O
utstanding(1)
512600
Warrants
Outstanding
(2)39
250C
urrentCapitalization
17034
784Pro
Forma
Issuances:IgD
raSolM
ilestone1
306272
Assignm
entAgreem
ent80000
ProForm
aC
apitalization18
421056
Weighted
averageexercise
price:$425
Weighted
averageexercise
price:$657
29
Sorrento
Therapeutics
Next
Generation
Cancer
Therapeutics
Contact:H
enryJi
PresidentandC
EO
hji@sorrentotherapeutics
com(858)
6686923
C
ynviloq:Interim
Results
fromPhase
3M
BC
Study
Phase3
studyin
MB
CS
umm
aryof
ClinicalE
xposuresStage
TrialPatients
Phase1
MT
D80
MB
CN
SC
LC
Phase2
259PC
OC
BC
Phase3
MB
C105
PostMarketM
BC
NS
CL
C502
(Safety)
Total946
US
approvalforA
braxane®in
MB
Cand
NSC
LC
fornon
inferiorityagainstT
axol®based
onO
RR
No
obviousethnic
differencesseen
between
OR
Rin
trials*
Interimdata
fromtrial;O
Sand
PFS
analysesongoing
4540
3530
2520
1510
50
p=
003
p=
0001
p=
0025
n=105n=
104n=
209n=
205n=
81n=82
Cynviloq™
Taxol®
Abraxane©
CA
012T
axol©A
braxane©T
axol©South
Korea*
United
States
China
31
Sim
ulatedP
KParam
etersS
upportiveof
BE
:C
ynviloq™vs
Abraxane®
Com
parisonof
mean
non-compartm
entalpharmacokinetic
parameters
ofC
ynviloq™(T
)and
Abraxane®
(R)
@260
mg/m
2w
ith30
min
infusiontim
e:C
max
Ratio
AU
Cinf
Ratio
(ng/mL
)C
max(T
)/Cm
ax(R)
(ng*h/mL
)A
UC
inf(T)/A
UC
inf(R)
CynviloqT
M19486
22198(S
imulated
PK)
996%
1092%
Abraxane®
1955620324
(ActualP
K)*
Note:Internalcalculations
doneas
95%C
IPer
FDA
requirement
ratioT
/R(C
max
andA
UC
inf)m
ustbew
ithin80-125%
(90%confidence
intervalor
CI)
Cynviloq™
dataon
file32 *
Gardner
etal2008
W
hyA
ntibodyT
herapeuticsC
linicaltrackrecord
ofsafety
andefficacy
Mostsuccessfuldrug
classtoday
Excellenttargetspecificity
andaffinity
Lim
itedoff
targeteffectsPredictable
PK
/PD
propertiesG
oodserum
halflife
Effector
functionsR
ecruitmentof
patient’sim
mune
systemagainstdiseased
cellsT
unabledrug
characteristicsE
ngineeringof
PKand
effectorfunctions
Targeted
deliveryof
cytotoxicdrugs
Antibody
Drug
Conjugates
(AD
C)
andA
ntibodyform
ulatedD
rugC
onjugates(A
fDC
)Feb
regionH
ingeregion
Febregion
Fcregion
FebFc
HL
cv33s
T
op10
SellingT
herapeuticA
ntibodies(>
$50B)
2012Sales
mA
bT
argetCom
panies(U
S$
billions)*U
SG
lobalH
umira
(Adalim
umab)
TN
FA
bbott;Esai4
49
3E
nbrel(Etanercept)
TN
FA
mgen;Pfizer;T
akeda4
08
0R
ituxan(R
ituximab)
CD
20R
oche3
37
0R
emicade
(Infliximab)
TN
FJ&
J;Merck;M
itsubishiTanabe
36
66
Herceptin
(Trastuzum
ab)H
ER
2R
oche1
76
2A
vastin(B
evacizumab)
VE
GF
Roche
26
61
Lucentis
(Ranibizum
ab)V
EG
FN
ovartis;Roche
16
40
Erbitux
(Cetuxim
ab)E
GFR
BM
S;M
erckSerono
07
18
Tysabri(N
atalizumab)
4integrin
Biogen
Idec0
91
6X
olair(O
malizum
ab)IgE
Novartis;R
oche0
71
334